Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter

PACE - Pacing and Clinical Electrophysiology

Volumn 30, Issue 11, 2007, Pages 1331-1335

  Tercius, Alix J ^c   Kluger, Jeffrey ^c   Coleman, Craig I ^c   Michael White, C ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c NONE

Author keywords

Atrial fibrillation; Chemical conversion; Torsade de pointes

Indexed keywords

IBUTILIDE; MAGNESIUM SULFATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CARDIOVERSION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; COHORT STUDIES; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME;

EID: 35948977426     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2007.00866.x     Document Type: Article

References (28)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006 48: e149 246.
2. Cropp JS, Antal EG, Talbert RL. Ibutilide: A new class III antiarrythmic agent. Pharmacotherapy 1997 17: 1 9.
3. Vanderlugt JT, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK, Perry KT, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999 100: 369 375.
4. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Advanced cardiovascular life support: 7D: The tachycardia algorithms. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000 102: I158.
5. Henyan NH, Gillespie EL, White CM, Kluger J, Coleman CI. The impact of intravenous magnesium on post-cardiothoracic surgery atrial fibrillation and length of hospital stay: A meta-analysis. Ann Thorac Surg 2005 80: 2402 2406.
6. White CM, Xie J, Chow MSS, Kluger J. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 1999 19: 635 640.
7. Caron MF, Kluger J, Tsikouris JP, Ritvo A, Kalus JS, White CM. The effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 2003 23: 296 300.
8. Coleman CI, Kalus JS, Caron MF, Kluger J, White CM. Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients. Am J Health-Sys Pharm. 2004 61: 685 688.
9. Kalus JS, Spencer AP, Tsikouris JP, Chung JO, Kenyon KW, Ziska M, Kluger J, et al. Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter: The treatment with ibutilide and magnesium evaluation (TIME). Am J Health-Sys Pharm 2003 60: 2308 2312.
10. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study. Crit Care Med 1995 23: 1816 1824.
11. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001 79: 287 291.
12. Brodsky MA, Orlov MC, Capparelli EV, Allen BJ, Iseri LT, Ginkel M, Orlov YSK. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol 1994 73: 1227 9. Erratum in Am J Cardiol. 1994; 74:639.
13. Gullestad L, Birkeland K, Mølstad P, Høyer MM, Vanberg P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol 1993 16: 429 434.
14. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J 1993 14 (suppl H 88 92.
15. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations and triggered activity in canine Purkinje fibers: Effects of stimulation rate, potassium, and magnesium. Circulation 1989 79: 674 686.
16. Kaseda S, Gilmour RF, Zipes DP. Depressant effects of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine, and 4-aminopyridinein canine cardiac purkinje fibers. Am Heart J 1989 118: 458 466.
17. Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation 1988 77: 1395 1402.
18. Tarr M, Trank JW, Goertz KK. Intracellular magnesium affects I(K) in single frog atrial cells. Am J Physiol 1989 257: H1663 669.
19. Horie M, Irisawa H. Dual effects of intracellular magnesium on muscarinic potassium channel current in single guinea-pig atrial cells. J Physiol 1989 408: 313 332.
20. Valentin-Ranc C, Carier MF. Evidence for the direct interaction between tightly bound divalent metal ion and ATP on actin. J Biol Chem 1989 264: 20871 20880.
21. Alvarez R, Bruno JJ. Activation of cardiac adenylate cyclase: Hormonal modification of the magnesium ion requirement. Proc Natl Acad Sci USA 1977 74: 92 95.
22. White RE, Hartzell HC. Effects of intracellular free magnesium on calcium current in isolated myocites. Science 1988 239: 778 80.
23. Chiese M, Inesi G. Mg++ and Mn++ modulation of Ca++ transport and ATPase activity in sarcoplasmic reticulum vesicles. Arch Biochem Biophys 1981 208: 586 592.
24. Hartzell HC, White RE. Effects of magnesium on inactivation of the voltage-gated calcium current in cardiac myocytes. J Gen Physiol 1989 94: 745 746.
25. Merot J, Charpentier F, Poinier JM, Coutris G, Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res. 1999 44 (2 303 14.
26. Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S, Scheinman MM. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation. 2001 103: 253 257
27. Naegeli B, Straumann E, Bertel O. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods. Int J Cardiol 2005 99: 283 287.
28. Frangakris N, Papadopoulos N, Papanastiou S, Kozirakis M, Maligkos G, Tsaritsaniotis E, Katsaris G. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. Pacing Clin Electrophysiol 2005 28: 954 961.